April 20, 2026
Jonathan Riess, MD, MS, and Nicholas Villanueva, MD, reflect on whether the field is becoming more biologically or data driven, concluding that both are increasingly intertwined. They discuss the move toward molecularly informed personalization, key unanswered questions around identifying patients who benefit most from intensification, and the need for better biomarkers to guide safe treatment de-escalation.
Related Posts
The Evolution of Frontline Therapy in EGFR-Mutant NSCLC
Interpreting Overall Survival Data With Combination Strategies in EGFR-Mutant NSCLC
Rethinking High-Risk EGFR-Mutant NSCLC
Integrating ctDNA Into Frontline Decision-Making in EGFR-Mutant NSCLC
Sequencing Strategies After Frontline Intensification in EGFR-Mutant NSCLC
